Fenfluramine Provides Clinical Benefit in Adults and Children with Dravet Syndrome: Real-World Experience from the European Early Access Program

Background/Purpose: In a recently completed phase 3 program, patients with Dravet syndrome (DS) treated with fenfluramine demonstrated sustained, profound reductions in seizure frequency, prolonged periods of seizure freedom, and improvement in executive functions. The European Early Access Program (EU-EAP) was initiated to allow pre-approval access to fenfluramine.